- Home
- GRFS
GRFS
Grifols S.A.
as 07-26-2024 4:00pm EST
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
| Founded: | 1940 | Country: | Spain |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.0B | IPO Year: | 2006 |
| Target Price: | $10.50 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Sell | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.10 | EPS Growth: | -70.97 |
| 52 Week Low/High: | $5.30 - $12.15 | Next Earning Date: | 07-28-2022 |
| Revenue: | $7,324,418,889 | Revenue Growth: | 8.71% |
| Revenue Growth (this year): | 8.84% | Revenue Growth (next year): | 7.12% |
Latest Grifols S.A. News
GRFS Breaking Stock News: Dive into GRFS Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
Three Stocks Estimated To Be Trading With Intrinsic Discounts Between 35.9% And 49.7%
Investopedia
17 days ago
Grifols Family Shareholders, Brookfield in Talks To Take Firm Private
MT Newswires
18 days ago
Grifols Shares Surge on Take-Private Talks
MT Newswires
18 days ago
European Equities Close Mixed in Monday Trading
Morningstar Research
18 days ago
Analyst Report: Grifols, S.A.
Benzinga
18 days ago
Beleaguered Spanish Drug Firm Grifols Stock Jumps On Monday - Here's Why
MT Newswires
18 days ago
Market Chatter: Grifols Says Founding Family, Brookfield Weigh Takeover Bid
Bloomberg
19 days ago
Grifols Says Founding Family, Brookfield Weigh Takeover Bid
Compare GRFS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GRFS Grifols S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.